A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

Headache · 2015 · PMC4320758 · PMID 25355310

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

approached the level of significanceP = .05actually significant

Patients in the AVP-825 treatment group experienced improved total migraine freedom that was significant at 1 hour and approached the level of significance ( P = .05) at the 2-hour time point.

also in 48 other papers

did not reach statistical significanceno p-value reported

Although reductions in migraine-associated symptoms (nausea, phonophobia, photophobia, and vomiting) were also observed, the between-group difference for most symptoms did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.